04:10 AM EDT, 06/24/2024 (MT Newswires) -- Fractyl Health ( GUTS ) said Sunday its Rejuva gene therapy program showed potential to treat obesity and type 2 diabetes in preclinical testing on mice.

The company said Rejuva showed sustained weight maintenance and body composition improvement by mimicking the release of glucagon-like peptide 1 from the pancreas.

Obese mice given Rejuva were shown to have reduced fat mass by 21% versus 16% of body weight with anti-obesity drug semaglutide at the end of four weeks, the company said.

Rejuva also stopped weight and glycemic rebound after semaglutide withdrawal, Fractyl Health ( GUTS ) said.

Price: 5.2300, Change: +0.72, Percent Change: +15.96